Vildagliptin (Galvus)
DPP-4 inhibitor · DPP-4 class · oral smd · Novartis
Top dose
50 mg BID
HbA1c reduction
-0.85%
at week 24 · efficacy
AE discontinuation
2.5%
Status
approved
Pivotal trial
- Trial
- Monotherapy (HbA1c)
- Indication
- type 2 diabetes
- Duration
- 24 weeks
- ClinicalTrials.gov
- NCT00099918
- Sponsor
- Novartis
Notes
Galvus: Novartis's DPP-4, a mainstay in Europe and emerging markets (not marketed in the US). HbA1c ~-0.8 to -0.9% at 50 mg twice daily.